MA41337A - Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3 - Google Patents

Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3

Info

Publication number
MA41337A
MA41337A MA041337A MA41337A MA41337A MA 41337 A MA41337 A MA 41337A MA 041337 A MA041337 A MA 041337A MA 41337 A MA41337 A MA 41337A MA 41337 A MA41337 A MA 41337A
Authority
MA
Morocco
Prior art keywords
receptor modulators
derivatives used
piperazine derivatives
cxcr3 receptor
hydroxyalkyl piperazine
Prior art date
Application number
MA041337A
Other languages
English (en)
Inventor
Eva Caroff
Emmanuel Meyer
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA41337A publication Critical patent/MA41337A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de formule (i) dans laquelle n, x, r<sup>1</sup> et r<sup>2</sup> sont tels que définis dans la description; des sels pharmaceutiquement acceptables de ceux-ci, et l'utilisation de tels composés en tant que médicaments, en particulier en tant que modulateurs du récepteur cxcr3
MA041337A 2015-01-15 2016-01-14 Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3 MA41337A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2015050696 2015-01-15

Publications (1)

Publication Number Publication Date
MA41337A true MA41337A (fr) 2017-11-22

Family

ID=55129886

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041337A MA41337A (fr) 2015-01-15 2016-01-14 Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3

Country Status (38)

Country Link
US (1) US10053457B2 (fr)
EP (1) EP3245203B1 (fr)
JP (1) JP6337218B2 (fr)
KR (1) KR101967083B1 (fr)
CN (1) CN107250133B (fr)
AR (1) AR103414A1 (fr)
AU (1) AU2016207988B2 (fr)
BR (1) BR112017015093A2 (fr)
CA (1) CA2972952C (fr)
CL (1) CL2017001831A1 (fr)
CO (1) CO2017008156A2 (fr)
CY (1) CY1121361T1 (fr)
DK (1) DK3245203T3 (fr)
EA (1) EA032927B1 (fr)
ES (1) ES2709985T3 (fr)
HK (1) HK1246789B (fr)
HR (1) HRP20190024T1 (fr)
HU (1) HUE042559T2 (fr)
IL (1) IL253411B (fr)
LT (1) LT3245203T (fr)
MA (1) MA41337A (fr)
MX (1) MX2017009288A (fr)
MY (1) MY187614A (fr)
NZ (1) NZ734542A (fr)
PE (1) PE20171100A1 (fr)
PH (1) PH12017501280B1 (fr)
PL (1) PL3245203T3 (fr)
PT (1) PT3245203T (fr)
RS (1) RS58349B1 (fr)
SA (1) SA517381905B1 (fr)
SG (1) SG11201705617XA (fr)
SI (1) SI3245203T1 (fr)
TN (1) TN2017000278A1 (fr)
TR (1) TR201900680T4 (fr)
TW (1) TWI693221B (fr)
UA (1) UA119805C2 (fr)
WO (1) WO2016113344A1 (fr)
ZA (1) ZA201705486B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201807959T4 (tr) 2013-07-22 2018-06-21 Idorsia Pharmaceuticals Ltd 1-(Piperazın-1-il)-2- ([1,2,4] triazol-1-il)-etanon türevleri.
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR103399A1 (es) * 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
RS58349B1 (sr) * 2015-01-15 2019-03-29 Idorsia Pharmaceuticals Ltd Hidroksialkil-piperazinski derivati kao modulatori cxcr3 receptora
WO2018011265A1 (fr) * 2016-07-13 2018-01-18 Idorsia Pharmaceuticals Ltd Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3
WO2020060964A1 (fr) * 2018-09-18 2020-03-26 Alxerion Biotech Corp. Dérivés de 1, 2, 4-oxadiazole et leurs utilisations
CA3205745A1 (fr) * 2021-01-28 2022-08-04 Dominik FOSSHAG Forme cristalline d'un derive de piperazinyl-thiazole
EP4583878A1 (fr) 2022-09-09 2025-07-16 Idorsia Pharmaceuticals Ltd Combinaison pharmaceutique comprenant un anticorps anti-cd3 et un antagoniste de cxcr3

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2433025A1 (fr) 2001-01-23 2002-08-01 Chaoyu Xie Piperidines/piperazines substituees utilisees comme agonistes du recepteur de melanocortine
JP2004523530A (ja) 2001-01-23 2004-08-05 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニストとしてのピペラジンおよびピペリジン誘導体
EP1363898A4 (fr) 2001-03-02 2004-12-08 Bristol Myers Squibb Co Composes utiles comme modulateurs de recepteurs de la melanocortine et compositions pharmaceutiques les comprenant
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
DK1531822T3 (da) 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
GB0315203D0 (en) 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
WO2005035534A1 (fr) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. Composes a anneau bicyclique heterocyclique et a anneau tricyclique heterocyclique et medicaments les contenant
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050119252A1 (en) 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
AU2004293026B2 (en) 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
US20060276465A1 (en) 2003-12-26 2006-12-07 Eisai R&D Management Co., Ltd. 1,2-di(cyclic) substituted benzene compounds
CN101437514B (zh) 2004-10-22 2012-04-25 詹森药业有限公司 C-fms激酶抑制剂
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
WO2006091428A2 (fr) 2005-02-16 2006-08-31 Schering Corporation Pyrazinyl-piperazine-piperidines substitutees heteroaryle a activite antagoniste cxcr3
CN101189238A (zh) 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的哌嗪-哌啶
CA2598458A1 (fr) 2005-02-16 2006-08-24 Schering Corporation Piperazine-piperidines pyrazinyl substituees a activite antagoniste des cxcr3
US7566718B2 (en) 2005-02-16 2009-07-28 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
CN101163692B (zh) 2005-02-16 2012-01-18 先灵公司 具有cxcr3拮抗活性的杂环取代的哌嗪
JP2008530216A (ja) 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有する、複素環で置換された新規のピリジンまたはフェニル化合物
AU2006214378A1 (en) 2005-02-16 2006-08-24 Pharmacopeia, Inc. Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
US20070010523A1 (en) 2005-06-22 2007-01-11 Chemocentryx, Inc. Azaindazole compounds and methods of use
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
US20080312215A1 (en) 2005-06-28 2008-12-18 Pharmacopeia Drug Discovery, Inc. Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
TW200738701A (en) 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
EP1937666B1 (fr) 2005-10-11 2012-02-22 Schering Corporation Composes heterocycliques substitues ayant une activite antagoniste vis-a-vis du cxcr3
AU2006304897B2 (en) 2005-10-18 2012-07-12 Janssen Pharmaceutica N.V. Method of inhibiting FLT3 kinase
US20090143413A1 (en) * 2005-11-29 2009-06-04 Adams Alan D Thiazole Derivatives as CXCR3 Receptor Modulators
US20070126158A1 (en) 2005-12-01 2007-06-07 3M Innovative Properties Company Method of cleaning polymeric mold
EP1962605A2 (fr) * 2005-12-12 2008-09-03 Merck & Co., Inc. Derives de 2-arylthiazole en tant que modulateurs du recepteur cxcr3
WO2007076318A2 (fr) 2005-12-21 2007-07-05 Smithkline Beecham Corporation Antagonistes de cxcr3 dérivés du camphre
EP1988900A2 (fr) 2006-02-23 2008-11-12 Merck & Co., Inc. Derives de pyridine, de pyrimidine et de pyrazine en tant que modulateurs du recepteur cxcr3
PE20071144A1 (es) 2006-03-21 2008-01-10 Schering Corp COMPUESTOS HETEROCICLICOS DE PIRIDINA SUSTITUIDA COMO ANTAGONISTAS DEL RECEPTOR 3 DE a-QUIMIOCINA (CXCR3)
EP2397138B1 (fr) 2006-04-20 2013-12-11 Janssen Pharmaceutica NV Dérivés d'amides aromatiques comme inhibiteurs de la kinase C-KIT
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
FR2903405B1 (fr) 2006-07-04 2011-09-09 Pasteur Institut Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
AR061975A1 (es) 2006-07-14 2008-08-10 Schering Corp Compuestos de piperazina 1,4-sustituida con actividad antagonista de cxcr3, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de quimioquina cxcr3
WO2008013622A2 (fr) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Amides azocycliques fongicides
EP2094688A1 (fr) 2006-12-22 2009-09-02 Schering Corporation Composés hétérocycliques à activité antagoniste des cxcr3
WO2008091594A2 (fr) 2007-01-24 2008-07-31 E. I. Du Pont De Nemours And Company Mélanges fongicides
PL2121660T3 (pl) 2007-01-25 2015-06-30 Du Pont Amidy grzybobójcze
JP2010535711A (ja) 2007-08-03 2010-11-25 シェーリング コーポレイション 複素環式置換ピペラジンを用いる、ｃｘｃｒ３媒介性疾患の処置方法
TWI428091B (zh) 2007-10-23 2014-03-01 Du Pont 殺真菌劑混合物
EP2234971A1 (fr) 2007-12-18 2010-10-06 Schering Corporation Procédé et intermédiaires pour la synthèse de pipérazines substituées hétérocycliques avec une activité antagoniste du cxcr3
EP2402332A3 (fr) 2008-01-25 2014-10-29 E.I. Du Pont De Nemours And Company Composés hétérocycliques fongicides
BRPI0905758A2 (pt) 2008-01-25 2015-07-14 Du Pont Composto, método de controle de doenças de plantas e composição fungicida
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
MX2010011879A (es) 2008-04-30 2010-12-06 Bayer Cropscience Ag Esteres y tioesteres del acido tiazol-4-carboxilico como agentes fitoprotectores.
KR20110067052A (ko) 2008-10-01 2011-06-20 바이엘 크롭사이언스 아게 식물 보호제로서의 헤테로사이클릴 치환된 티아졸
KR101052065B1 (ko) 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
US8618137B2 (en) 2008-12-02 2013-12-31 E I Du Pont De Nemours And Company Fungicidal heterocyclic compounds
BRPI0923366A2 (pt) 2008-12-11 2019-09-24 Bayer Cropscience Ag éteres e hodrazonas de oxima de tiazolila como agentes protetors de culturas.
JP5807971B2 (ja) * 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｘｃｒ３受容体アンタゴニスト
US8362249B2 (en) 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
EP2272846A1 (fr) 2009-06-23 2011-01-12 Bayer CropScience AG Dérivés de thiazolylpipéridine en tant que fongicide
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
AU2010283832A1 (en) 2009-08-12 2012-02-23 Syngenta Participations Ag Microbiocidal heterocycles
WO2011051243A1 (fr) 2009-10-29 2011-05-05 Bayer Cropscience Ag Combinaisons de composé actif
CN102712634B (zh) 2009-10-30 2016-04-06 拜耳知识产权有限责任公司 杂芳基哌啶和杂芳基哌嗪衍生物
WO2011076699A1 (fr) 2009-12-21 2011-06-30 Bayer Cropscience Ag Bis(difluorométhyl)pyrazoles utilisés comme fongicides
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
BR112012027762B1 (pt) 2010-04-28 2018-06-05 Bayer Intellectual Property Gmbh Derivados de cetoheteroarilpiperidina e - piperazina como fungicidas
US8815775B2 (en) 2010-05-18 2014-08-26 Bayer Cropscience Ag Bis(difluoromethyl)pyrazoles as fungicides
EP2571866A1 (fr) 2010-05-20 2013-03-27 E.I. Du Pont De Nemours And Company Oximes et hydrazones fongicides
JP2013528169A (ja) 2010-05-27 2013-07-08 バイエル・クロップサイエンス・アーゲー 殺菌剤としてのピリジニルカルボン酸誘導体
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
EP2632922B1 (fr) 2010-10-27 2019-02-27 Bayer CropScience Aktiengesellschaft Hétéroarylpipéridine et dérivés d'hétéroarylpipéridine comme fongicide
EP2643312B1 (fr) 2010-11-25 2014-09-10 Syngenta Participations AG Hétérocycles microbicides
KR20140017520A (ko) 2010-12-17 2014-02-11 이 아이 듀폰 디 네모아 앤드 캄파니 살진균제 아조사이클릭 아미드
WO2012104273A1 (fr) 2011-02-01 2012-08-09 Bayer Cropscience Ag Dérivés d'hétéroarylpipéridine et d'hétéroarylpipérazine utilisés comme fongicides
BR112013020419A2 (pt) 2011-02-10 2016-07-12 Syngenta Participations Ag microbicidas derivados de pirazol
US8748432B2 (en) 2011-02-10 2014-06-10 Syngenta Participations Ag Microbiocidal pyrazole derivatives
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US10004232B2 (en) 2011-09-15 2018-06-26 Bayer Intellectual Property Gmbh Piperidine pyrazoles as fungicides
BR112014009086A2 (pt) 2011-10-18 2017-05-09 Syngenta Participations Ag derivados pirazol microbicidas
BR112014009037A2 (pt) 2011-10-18 2017-05-09 Syngenta Participations Ag derivados pirazol microbicidas
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
JP6258867B2 (ja) 2012-01-25 2018-01-10 ノバルティス アーゲー 複素環式化合物およびその使用方法
MX352181B (es) * 2012-02-02 2017-11-13 Idorsia Pharmaceuticals Ltd Compuestos 4- (benzoimidazol-2-il) -tiazol y derivados aza relacionados.
WO2013127808A1 (fr) 2012-03-02 2013-09-06 Syngenta Participations Ag Dérivés de pyrazole microbicides
WO2013127784A1 (fr) 2012-03-02 2013-09-06 Syngenta Participations Ag Dérivés de pyrazole microbicides
DK2855453T3 (en) * 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives
WO2014062938A1 (fr) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Modulateurs du récepteur gamma orphelin associé aux rétinoïdes (rory)
WO2014075873A1 (fr) 2012-11-13 2014-05-22 Syngenta Participations Ag Dérivés microbicides de pyrazole
WO2014075874A1 (fr) 2012-11-13 2014-05-22 Syngenta Participations Ag Dérivés microbicides de pyrazole
EA029056B1 (ru) 2012-12-11 2018-02-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение
DK3013821T3 (en) 2013-06-24 2018-06-18 Bayer Cropscience Ag PIPERIDINCARBOXYLIC ACID DERIVATIVES AS FUNGICIDES
TR201807959T4 (tr) * 2013-07-22 2018-06-21 Idorsia Pharmaceuticals Ltd 1-(Piperazın-1-il)-2- ([1,2,4] triazol-1-il)-etanon türevleri.
WO2015026683A1 (fr) 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Composés inhibant l'activité enzymatique de la kinase à répétitions riches en leucine
AR099789A1 (es) * 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR102256A1 (es) * 2014-10-15 2017-02-15 Actelion Pharmaceuticals Ltd Derivados biaromáticos básicos antibacterianos con sustitución de aminoalcoxi
RS58349B1 (sr) * 2015-01-15 2019-03-29 Idorsia Pharmaceuticals Ltd Hidroksialkil-piperazinski derivati kao modulatori cxcr3 receptora
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3

Also Published As

Publication number Publication date
MY187614A (en) 2021-10-04
KR101967083B1 (ko) 2019-04-08
CO2017008156A2 (es) 2017-11-30
EA032927B1 (ru) 2019-08-30
PE20171100A1 (es) 2017-08-07
EP3245203A1 (fr) 2017-11-22
AU2016207988B2 (en) 2019-08-15
TWI693221B (zh) 2020-05-11
CN107250133A (zh) 2017-10-13
US20180009799A1 (en) 2018-01-11
AU2016207988A1 (en) 2017-08-31
HRP20190024T1 (hr) 2019-02-22
EA201791600A1 (ru) 2018-03-30
PH12017501280B1 (en) 2020-10-23
PT3245203T (pt) 2019-02-08
KR20170102010A (ko) 2017-09-06
JP2018502161A (ja) 2018-01-25
IL253411B (en) 2020-08-31
DK3245203T3 (en) 2019-02-18
TW201632519A (zh) 2016-09-16
NZ734542A (en) 2023-02-24
SI3245203T1 (sl) 2019-03-29
CA2972952A1 (fr) 2016-07-21
TN2017000278A1 (en) 2019-01-16
TR201900680T4 (tr) 2019-02-21
HK1246789B (en) 2019-11-22
JP6337218B2 (ja) 2018-06-06
SA517381905B1 (ar) 2021-04-01
CL2017001831A1 (es) 2018-05-11
US10053457B2 (en) 2018-08-21
CY1121361T1 (el) 2020-05-29
LT3245203T (lt) 2019-02-11
EP3245203B1 (fr) 2018-11-14
CA2972952C (fr) 2021-01-05
HUE042559T2 (hu) 2019-07-29
ES2709985T3 (es) 2019-04-22
SG11201705617XA (en) 2017-08-30
CN107250133B (zh) 2020-09-15
RS58349B1 (sr) 2019-03-29
WO2016113344A1 (fr) 2016-07-21
UA119805C2 (uk) 2019-08-12
IL253411A0 (en) 2017-09-28
PH12017501280A1 (en) 2018-01-15
AR103414A1 (es) 2017-05-10
ZA201705486B (en) 2019-06-26
BR112017015093A2 (pt) 2018-04-17
PL3245203T3 (pl) 2019-05-31
MX2017009288A (es) 2017-10-11

Similar Documents

Publication Publication Date Title
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2022011354A (es) Compuestos de pirimidina fusionados como moduladores de kcc2.
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
MA42109A (fr) Amides hétérocycliques utilisés en tant qu&#39;inhibiteurs de kinase
MA39317A1 (fr) Dérivés de nucléosides à substitution 4&#39;-difluorométhyle utilisés en tant qu&#39;inhibiteurs de la réplication de l&#39;arn du virus de la grippe
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
PH12016501440A1 (en) Novel heterocyclic compounds
CU20170105A7 (es) Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
MA40281B1 (fr) Composés de pyrazole et leur utilisation en tant qu&#39; agents de blocage des canaux calciques de type t
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
ECSP17069696A (es) Compuestos novedosos
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA37142B1 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
JOP20210004A1 (ar) عوامل تحلّل مستقبلات الإستروجين الانتقائية
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d&#39;orexine
MX394108B (es) Derivados de indol n-sustituidos.
MX2017011978A (es) Analogos deuterados de etifoxina, sus derivados y usos de estos.
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
MA38854B1 (fr) Dérivés amides utilisés en tant qu&#39;antagonistes des récepteurs de l&#39;acide lysophosphatidique